Proposed Collection; 60-Day Comment Request: Federal COVID Response-Audience Feedback To Inform Ongoing Messaging and Strategies for “Combat COVID”, 50143-50144 [2021-19383]
Download as PDF
<![CDATA[
50143
Federal Register / Vol. 86, No. 170 / Tuesday, September 7, 2021 / Notices
2021, times are from 10 a.m. to 4:30
p.m. on November 4th and 10 a.m. to
1:30 p.m. on November 5th. The
meeting is closed to the public.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: August 31, 2021.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
Proposed Collection; 60-Day Comment
Request: Federal COVID Response—
Audience Feedback To Inform Ongoing
Messaging and Strategies for ‘‘Combat
COVID’’
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
Ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) Ways to minimize the
burden of the collection of information
on those who are to respond, including
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology.
Proposed Collection Title: Federal
COVID Response—Audience Feedback
to Inform Ongoing Messaging and
Strategies for ‘‘Combat COVID,’’ OMB
#0925–0769, exp.12/31/2021,
EXTENSION, National Institutes of
Health (NIH).
Need and Use of Information
Collection: The purpose of the
information collection is to collect
routine feedback from the Combat
COVID Initiative’s two target audiences
(the general public and healthcare
providers) to identify evolving needs
and better disseminate relevant
information as it relates to COVID–19
treatment and ACTIV clinical trial
resources, specifically. Data collected
will be used to inform the development
and broad dissemination of Combat
COVID resources, including new or
enhanced message and material
concepts (e.g., social media ads, digital
display ads, out-of-home ads), and/or
web pages (combatcovid.hhs.gov).
Because the COVID–19 treatment
landscape continues to evolve, new
evidence-based information continues
to come to the forefront, and audience
needs continue to change, it is critical
for the Federal COVID Response (FCR)
Team to collect quick audience feedback
from the general public (especially from
groups who have not historically been
well-represented in clinical trials) and
healthcare providers to identify these
evolving needs. By understanding target
audience needs, the FCR team will be
able to properly develop and broadly
disseminate relevant COVID–19
treatment and ACTIV clinical trial
resources.
OMB approval is requested for 1 year.
There are no costs to respondents other
than their time. The total estimated
annualized burden hours are 3,528.
National Institutes of Health
[FR Doc. 2021–19233 Filed 9–3–21; 8:45 am]
BILLING CODE 4140–01–P
AGENCY:
National Institutes of Health,
HHS.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
ACTION:
In compliance with the
requirement of the Paperwork
Reduction Act of 1995 to provide
opportunity for public comment on
proposed data collection projects, the
National Institutes of Health (NIH),
Clinical Center (CC) will publish
periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 60 days of the date of this
publication.
SUMMARY:
National Institutes of Health
National Institute of Nursing Research;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Nursing Research Special Emphasis Panel;
Institutional Training Grants.
Date: September 24, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Nursing
Research, 6701 Democracy Boulevard,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ming Yan, MD, Ph.D.,
Scientific Review Officer, Immunology
(IMM), DPPS, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 4205, Bethesda, MD 20892,
yanming@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.361, Nursing Research,
National Institutes of Health, HHS)
Dated: September 2, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–19364 Filed 9–3–21; 8:45 am]
BILLING CODE 4140–01–P
sradovich on DSKJLST7X2PROD with NOTICES
Notice.
To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Ms. Mikia P. Currie, Office of
Policy for Extramural Research
Administration, 6705 Rockledge Drive,
Suite 350, Bethesda, Maryland 20892, or
call a non-toll free number (301) 435–
0941 or Email your request, including
your address to:
ProjectClearanceBranch@mail.nih.gov.
Formal requests for additional plans and
instruments must be requested in
writing.
FOR FURTHER INFORMATION CONTACT:
Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: written
comments and/or suggestions from the
public and affected agencies are invited
to address one or more of the following
points: (1) Whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
SUPPLEMENTARY INFORMATION:
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondent
Consumer Audience Feedback Team Screener .............................................
HCP Audience Feedback Team Screener ......................................................
VerDate Sep<11>2014
00:30 Sep 04, 2021
Jkt 253001
PO 00000
Frm 00132
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
120
40
U:\07SEN1.SGM
1
1
07SEN1
Average time
per response
(in hours)
5/60
5/60
Total annual
burden hours
10
3
50144
Federal Register / Vol. 86, No. 170 / Tuesday, September 7, 2021 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Number of
respondents
Type of respondent
Average time
per response
(in hours)
Total annual
burden hours
Consumer Audience Feedback Activity ...........................................................
HCP Audience Feedback Activity ....................................................................
Benchmark & Follow-Up Web Surveys—Consumer Audience .......................
Benchmark & Follow-Up Web Survey—HCP Audience ..................................
60
20
2,000
300
8
8
5
5
1
1
15/60
15/60
480
160
2,500
375
Total ..........................................................................................................
2,540
12,300
........................
3,528
Dated: September 1, 2021.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes
of Health.
[FR Doc. 2021–19383 Filed 9–3–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
sradovich on DSKJLST7X2PROD with NOTICES
Number of
responses per
respondent
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
High Throughput Screening.
Date: October 8, 2021.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Joseph D Mosca, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5158,
MSC 7808, Bethesda, MD 20892, (301) 435–
2344, moscajos@csr.nih.gov.
Name of Committee: Surgical Sciences,
Biomedical Imaging and Bioengineering
Integrated Review Group Bioengineering,
Technology and Surgical Sciences Study
Section.
Date: October 12–13, 2021.
Time: 8:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Sep<11>2014
00:30 Sep 04, 2021
Jkt 253001
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Khalid Masood, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5120,
MSC 7854, Bethesda, MD 20892, (301) 435–
2392, masoodk@csr.nih.gov.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Science of Implementation in Health and
Healthcare Study Section.
Date: October 12–13, 2021.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Wenjuan Wang, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3154,
Bethesda, MD 20892, (301) 480–8667,
wangw22@mail.nih.gov.
Name of Committee: Biological Chemistry
and Macromolecular Biophysics Integrated
Review Group; Macromolecular Structure
and Function A Study Section.
Date: October 12–13, 2021.
Time: 10:00 a.m. to 9:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: David R Jollie, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4166,
MSC 7806, Bethesda, MD 20892, (301) 408–
9072, jollieda@csr.nih.gov.
Name of Committee: Applied Immunology
and Disease Control Integrated Review
Group; Vector Biology Study Section.
Date: October 12–13, 2021.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Liangbiao Zheng, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3214,
MSC 7808, Bethesda, MD 20892, (301) 402–
5671, zhengli@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
PO 00000
Frm 00133
Fmt 4703
Sfmt 4703
U:\07SEN1.SGM
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS).
Dated: August 31, 2021
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–19228 Filed 9–3–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; National Center for
Advancing Translational Sciences Special
Emphasis Panel.
Date: October 7, 2021.
Time: 9:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1037, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Nakia C. Brown, Ph.D.,
Scientific Review Officer, Office of Grants
Management and Scientific Review, National
Center for Advancing Translational Sciences,
National Institutes of Health, 6701
Democracy Boulevard, Room 1037, Bethesda,
07SEN1
]]>Agencies
[Federal Register Volume 86, Number 170 (Tuesday, September 7, 2021)]
[Notices]
[Pages 50143-50144]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-19383]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment Request: Federal COVID
Response--Audience Feedback To Inform Ongoing Messaging and Strategies
for ``Combat COVID''
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In compliance with the requirement of the Paperwork Reduction
Act of 1995 to provide opportunity for public comment on proposed data
collection projects, the National Institutes of Health (NIH), Clinical
Center (CC) will publish periodic summaries of proposed projects to be
submitted to the Office of Management and Budget (OMB) for review and
approval.
DATES: Comments regarding this information collection are best assured
of having their full effect if received within 60 days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data
collection plans and instruments, submit comments in writing, or
request more information on the proposed project, contact: Ms. Mikia P.
Currie, Office of Policy for Extramural Research Administration, 6705
Rockledge Drive, Suite 350, Bethesda, Maryland 20892, or call a non-
toll free number (301) 435-0941 or Email your request, including your
address to: [email protected]. Formal requests for
additional plans and instruments must be requested in writing.
SUPPLEMENTARY INFORMATION: Section 3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: written comments and/or suggestions
from the public and affected agencies are invited to address one or
more of the following points: (1) Whether the proposed collection of
information is necessary for the proper performance of the function of
the agency, including whether the information will have practical
utility; (2) The accuracy of the agency's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) Ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) Ways
to minimize the burden of the collection of information on those who
are to respond, including the use of appropriate automated, electronic,
mechanical, or other technological collection techniques or other forms
of information technology.
Proposed Collection Title: Federal COVID Response--Audience
Feedback to Inform Ongoing Messaging and Strategies for ``Combat
COVID,'' OMB #0925-0769, exp.12/31/2021, EXTENSION, National Institutes
of Health (NIH).
Need and Use of Information Collection: The purpose of the
information collection is to collect routine feedback from the Combat
COVID Initiative's two target audiences (the general public and
healthcare providers) to identify evolving needs and better disseminate
relevant information as it relates to COVID-19 treatment and ACTIV
clinical trial resources, specifically. Data collected will be used to
inform the development and broad dissemination of Combat COVID
resources, including new or enhanced message and material concepts
(e.g., social media ads, digital display ads, out-of-home ads), and/or
web pages (combatcovid.hhs.gov). Because the COVID-19 treatment
landscape continues to evolve, new evidence-based information continues
to come to the forefront, and audience needs continue to change, it is
critical for the Federal COVID Response (FCR) Team to collect quick
audience feedback from the general public (especially from groups who
have not historically been well-represented in clinical trials) and
healthcare providers to identify these evolving needs. By understanding
target audience needs, the FCR team will be able to properly develop
and broadly disseminate relevant COVID-19 treatment and ACTIV clinical
trial resources.
OMB approval is requested for 1 year. There are no costs to
respondents other than their time. The total estimated annualized
burden hours are 3,528.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average time
Type of respondent Number of responses per per response Total annual
respondents respondent (in hours) burden hours
----------------------------------------------------------------------------------------------------------------
Consumer Audience Feedback Team Screener........ 120 1 5/60 10
HCP Audience Feedback Team Screener............. 40 1 5/60 3
[[Page 50144]]
Consumer Audience Feedback Activity............. 60 8 1 480
HCP Audience Feedback Activity.................. 20 8 1 160
Benchmark & Follow-Up Web Surveys--Consumer 2,000 5 15/60 2,500
Audience.......................................
Benchmark & Follow-Up Web Survey--HCP Audience.. 300 5 15/60 375
---------------------------------------------------------------
Total....................................... 2,540 12,300 .............. 3,528
----------------------------------------------------------------------------------------------------------------
Dated: September 1, 2021.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes of Health.
[FR Doc. 2021-19383 Filed 9-3-21; 8:45 am]
BILLING CODE 4140-01-P
